This year marks the 10th anniversary of the clinical introduction of natriuretic peptides (NPs) in acute cardiovascular care. In 2002, the seminal Breathing NOT Properly Study was published in the New England Journal of Medicine and paved the way for the widespread clinical use of NPs. 1 This study was built on the knowledge gained from pioneering work from the group of Mark Richards and others. 2 Worldwide clinical research during the last decade has built a solid scientific fundament that allows clinicians to get a decent understanding of the clinical value of NPs in acute cardiovascular care. 1-17 The paper by Meisel et al. 18 adds to this understanding.
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Natriuretic peptides are cardiac hormones, which are predominately secreted from the heart in response to cardiac haemodynamic stress mediated by volume and pressure overload. NPs can be seen as quantitative markers of cardiac stress and heart failure summarizing the extent of systolic left ventricular dysfunction, diastolic left ventricular dysfunction, right ventricular dysfunction, and valvular dysfunction. Evidence from multiple large observational as well as randomized controlled trials supports the routine use of NPs in the early diagnosis of acute heart failure in patients presenting with acute dyspnea. [1] [2] [3] [4] [5] [6] [7] [8] In addition, NPs quantify disease severity and are therefore powerful predictors of morbidity and mortality in patients with heart failure, but also in other acute cardiovascular conditions including acute myocardial infarction, pulmonary embolism, and stroke. [15] [16] [17] They should, therefore, be considered for risk stratification in these patients. The lower the NP levels, the lower the risk of death or rehospitalization. The concept of NP-guided heart failure management is increasingly used as recent meta-analyses summarizing the individual data from the available rather small randomized controlled trials have shown a significant reduction in mortality associated with the regular use of NP measurement in the management of patients with chronic heart failure. 19 In conjunction with multiple other studies in this setting, the paper by Meisel et al. 18 Clearly, the specific setting, patient characteristics, the NP cut-off values applied, adjusting for important confounders including renal dysfunction and obesity, time from patient presentation to the availability of the NP value to the clinician, the extent of training and familiarity of the treating physicians with the appropriate use of NPs, and the treatments initiated in response to NP concentrations play an important role. 6. NPs measured at 24 or 48 hours or prior to discharge from the hospital, but not those measured initially in the emergency department, accurately predict the risk of readmission and mortality. 7. A single measurement of NPs in the emergency department does not impact on mortality. This is not surprising, as a diagnostic test can only impact on mortality if the treatment initiated in response to the information provided by the diagnostic test does have a profound effect on mortality. As none of our current treatments of acute heart failure has been shown to impact on mortality, improvements in the early diagnosis of acute heart failure can be expected to lead to an earlier improvement in dyspnoea, but not a reduction in mortality.
